<DOC>
	<DOC>NCT02505113</DOC>
	<brief_summary>To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.</brief_summary>
	<brief_title>Cavernous Transformation of Portal Veinï¼š Etiology, Diagnosis, Management and Prognosis</brief_title>
	<detailed_description>To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein. We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.</detailed_description>
	<mesh_term>Hypertension, Portal</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>All patients with CTPV. Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Portal Vein, Cavernous Transformation Of</keyword>
	<keyword>Hypertension, Portal</keyword>
</DOC>